

Lymphoma

Non-Hodgkin Lymphoma

Hodgkin Lymphoma

Previously Untreated

Previously Treated

 Subsequent
Salvage

 PD-1 Inhibitor
Naive

ECOG-ACRIN- EAQ211

 Social Genomic
Mechanisms of
Health Disparities
Among
Adolescent &
Young Adult (AYA)
Survivors of
Hodgkin and
Non-Hodgkin
Lymphoma

 PI: Advani
Sponsor:
ECOG-ACRIN

LYMHD0021

 Randomised
Phase III Trial w/
PET Response
Adapted Design
Comparing ABVD
+/- ISRT w/ A2VD
+/- ISRT in
Patients w/
Previously
Untreated Stage
IA/IIA Hodgkin
Lymphoma
(RADAR)

 PI: Advani
Sponsor:
University College
London

VAR0174

 Leveraging
Mindsets to
Improve Heal
& Wellbeing in
Patients with
Cancer

 PI: Crum
Sponsor: Stanford

[LYMHD0019](#)

[Phase II
Magrolimab and
Pembrolizumab in
Relapsed or
Refractory Classic
Hodgkin
Lymphoma](#)




 PI: Advani
Sponsor: Stanford



ECOG-ACRIN- EAQ211



 Social Genomic
Mechanisms of
Health Disparities
Among
Adolescent &
Young Adult (AYA)
Survivors of
Hodgkin and
Non-Hodgkin
Lymphoma

 PI: Advani
Sponsor:
ECOG-ACRIN

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
- [Link](#) Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy